New treatments for age-related macular degeneration.
Taylor
Hugh R
HR
Pezzullo
M Lynne
ML
Guymer
Robyn
R
D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003362:Cost-Benefit Analysis; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D018803:Models, Economic; D011306:Prescription Fees; D000069579:Ranibizumab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab